FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Immunologist from Erlangen shares his expertise on the soluble CD83 molecule

Besuch aus Erlangen-Nürnberg von Prof. Dr. Alexander Steinkasserer, Forschergruppe FOR 2240

Visiting Professor Dr. rer. nat. Alexander Steinkasserer (photo center right) came to Cologne on the 17th of November, 2016 and met with several projects of Cologne-based DFG research unit FOR 2240 “Angiogenesis, lymphangiogenesis and cellular immunity in inflammatory diseases of the eye”. Professor Steinkasserer is the Head of the Immune Modulation Department at the University Hospital Erlangen (Friedrich Alexander University of Erlangen-Nuremberg), and met with Univ.-Prof. Dr. med. Claus Cursiefen (photo left), Speaker of the FOR 2240 and Principle Investigator of Projects 1 & 2, and Univ.-Prof. Dr. rer. nat. Thomas Langmann, Vice-Speaker of the FOR 2240 and Principle Investigator of Project 6 “Role of the complement system and microglia in age-related macular degeneration”, as well as Priv.-Doz. Dr. Felix Bock (photo right), who, next to Prof. Cursiefen, is the Principle Investigator of FOR 2240 Project 1: “Induction of corneal transplant tolerance by anti(lymph)angiogenic therapy”, Ms. Ann-Charlott Schneider (photo center left), a PhD student working in Project 1, and Dr. med. Dipl.-Mol. Med. Deniz Hos, one of the Principle Investigators of Project 5 “Myeloid cell function in corneal hem- and lymphangiogenesis”. Professor Steinkasserer’s technical and scientific expertise was highly appreciated by the Principle Investigators and scientists.

The research areas that Professor Alexander Steinkasserer and his team focus on include immune-modulation in autoimmunity and transplantation by soluble CD83, transcriptional in vivo targeting of dendritic cells using the human CD83 promoter, in vivo targeting of dendritic cells to induce potent anti-tumoral immune responses directly in patients, intracellular signal transduction of CD83 in dendritic cells, immune-modulation by thymic stromal lymphopoietin (TSLP) and CD83, and the interaction between dendritic cells and viruses.

Prof. Steinkasserer gave a lecture on how the CD83 molecule modulates the immune systems by the induction of regulatory T cells, focusing on soluble CD83. He discussed what it blocks, what it down-modulates, and its property of inhibiting DC-T cell clustering. Its applications in areas such as multiple sclerosis, inflammatory bowel disease, and high-risk cornea transplantation were explored.

Related posts

DOG Rokohl

DOG Rokohl

March 22, 2022

FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize


Read more
RWA Schlereth 2022

Augenklinik RWA Schlereth 2022

February 18, 2022

Dr. Simona Schlereth wins RWA Science Award 2022


Read more
Yongwei Guo DOG

Yongwei Guo DOG

January 24, 2022

Dr. Yongwei Guo wins DOG Doctoral Award for outstanding dissertation


Read more

News

  • FOR 2240 Scientist Dr. Alexander C. Rokohl was awarded the Brewitt Publication Prize
  • Dr. Simona Schlereth wins RWA Science Award 2022
  • Dr. Yongwei Guo wins DOG Doctoral Award for outstanding dissertation
  • FOR 2240 scientist Dr. Alexander Rokohl wins DOG Science Prize “Dry Eye and Blepharitis/MGD”
  • Newly funded DFG project on ocular tyrosinase and lymphangiogenesis – affiliated to FOR2240

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck